1. At a Glance – The Silent ₹393 Cr Pharma Player Trying to Go Global
Here’s a ₹393 crore market cap pharma company sitting at ₹1,300 per share, delivering ₹94.78 crore in quarterly sales and ₹6.65 crore in quarterly profit, while the big boys of pharma are busy fighting patent wars.
Haleos Labs Limited (formerly SMS Lifesciences) is trading at a P/E of 19.8, Price-to-Book of 1.90, ROCE of 11.8%, and ROE of 10.8%. Over the last 3 months? Flat. Over 6 months? +18.5%. Over 3 years? A spicy 30.6% return.
Latest Q3 FY26 numbers show:
- Sales up 12% YoY
- Profit up 21% YoY
- OPM at 14.82%
- Debt reduced to ₹69.8 crore
- Promoter holding increased to 71.79%
Smallcap API manufacturer.
Regulated market approvals.
USFDA clean inspection.
ANVISA green signal for Brazil.
So the question is: Is this a slow and steady compounding lab, or just another API cycle passenger?
Let’s open the test tube.
2. Introduction – The Demerged Child Trying to Prove Itself
Haleos Labs is the demerged entity of SMS Pharmaceuticals. Think of it as the kid who moved out of the joint family business and said, “Now I’ll show you what I can do.”
Incorporated in 2006, it focuses purely on manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates.
Not formulations.
Not fancy brands.
Not retail chemist shelf drama.
Pure backend chemistry.
They operate out of Hyderabad and Vizag, with facilities approved by:
Recently, ANVISA (Brazil) inspection was successful. That’s not small news. Brazil is a serious regulated market.
They supply to:
Sun Pharma, Cipla, Teva, GSK, Dr Reddy’s, Mylan, Zydus.
Basically, the giants you see in the peer table.
Yet Haleos’ market cap is smaller than what some of these companies probably spend on marketing in a quarter.
So why the discount?
Let’s see.
3. Business Model – WTF Do They Even Do?
Okay, simple version.
They manufacture APIs.
APIs are the actual chemical molecules that make medicines work. When you buy a tablet, the API inside it is what treats your disease.
